Centre for Psychedelics Health & Research

Canada’s Multi-Disciplinary Hub for Psychedelic Research

We taking a comprehensive approach to exploring the potential of psychedelics to transform healthcare through clinical trials, biomarker innovation and education.

Leading the way in psychedelic research, training and education

Our Objectives:

  1. Advance psychedelic medicine and public health by conducting high-quality clinical research and fostering technological innovation
  2. Share knowledge to diverse populations through an extensive knowledge translation program
  3. Shape the future of psychedelic health by creating a collaborative network through training and networking events

News

November 2025

CPHR hosts a successful first Annual Scientific Meeting at Providence Care Hospital. 

A gathering of multi-disciplinary clinicians, researchers, trainees, and collaborators sharing research updates and strategic planning discussions.

May 2025

Launch of The Integration Session, a knowledge translation podcast for staying up-to-date with important advancements in psychedelic science and building connections across the field. 

The podcast episodes will be released bi-monthly in both audio and visual format on Spotify and YouTube, this initiative is led by Dr. Elena Koning

November 2024

Initiation of “Non-hallucinogenic Psilocybin (i.e., ‘micro-dosing’) for the Management of Moderate-to-severe Generalized Anxiety Disorder (GAD): Safety, Efficacy, and Potential Biomarker for Treatment Response”

Funded by Diamond Therapeutics and SEAMO Innovation, and led by Dr. Claudio Soares

November 2024

CPHR Led Successful Psychedelic Course at CPA Annual Meeting in Montreal

The 3-hour Course From Underground to Mainstream: Challenges and Opportunities for Psychedelics in Mental Health had more than 150 registrants/attendees, made possible thanks to the support received from OBI, CAN-BIND and Providence Care Hospital

November 2024

Initiation of Clinical Trial Exploring Electroencephalography (EEG) as a Biomarker for Psilocybin-Based Therapies

Funded by the Queen’s University Department of Psychiatry and led by Dr. Claudio Soares

October 2024

Successful Psychedelic Research Retreat with the Royal Ottawa’s Interventional Psychiatry Group

Led by Dr. J. Phillips to foment collaboration and capacity building in psychedelic research. The event included researchers and clinicians from the University of Ottawa, CAMH, University of Calgary, CPHR and CAN-BIND

October 2024

Completion of “24-Week, Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD)”

Funded by Clairvoyant Therapeutics and led by Dr. Claudio Soares

August 2024

The Inauguration of CPHR at Providence Care

The ceremony had the presence of leaders from Queen’s University, OBI, CAN-BIND and other national and international stakeholders. The event received ample media coverage, including CBC Ottawa, CTV Ottawa, The Kingstonist, CFRC Queen’s University, and Head Topics

CPHR is supported by the Ontario Brain Institute (OBI), the Canadian Biomarker Integration Network in Depression (CAN-BIND), and Providence Care Hospital.